Annovis raises $10 million to fund alzheimer's drug through phase 3 trial

April 10, 2026 8:31 AM

Annovis Bio Inc. (NYSE: ANVS) closed a $10 million underwritten public offering to fund operations through the second quarter of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found